Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07724548

Comparison Between Virtual vs in Person on Treatment Follow-up Visits of Radiotherapy

This study aims to evaluate the logistical feasibility and implementation of virtual versus in-person on-treatment follow up visits in a high-volume radiation oncology setting. It further seeks to assess and compare patient and physician satisfaction with both modalities through structured survey data, providing insight into the clinical utility, communication quality, and overall acceptability of telehealth integration during active cancer treatment.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Shaukat Khanum Memorial Cancer hospital & Research Centre

Lahore, Punjab Province, Pakistan

Location status: Recruiting

Location contact

Farah Asif, MBBS

CONTACT

[email protected]

04235905000 ext. 4280

About this study

Telemedicine and telehealth services, operationally defined as patient-provider interactions conducted through telecommunication technologies, have experienced widespread integration across diverse medical specialties. Prior to the onset of the coronavirus disease 2019 (COVID-19) pandemic, numerous clinical disciplines had adopted telemedicine modalities to enhance healthcare accessibility and improve patient convenience. The COVID-19 pandemic and its aftermath have precipitated an unprecedented acceleration in the adoption of telehealth services, profoundly reshaping healthcare delivery paradigms across multiple disciplines.

As of 2025, Pakistan continues to grapple with a substantial cancer burden, with more than 185,000 new cases and over 125,000 cancer-related deaths reported annually. Despite ongoing efforts to improve awareness, early detection, and treatment accessibility, major challenges persist-particularly regarding healthcare access in rural regions and the financial burden associated with cancer treatment. For patients undergoing primary treatment, the costs of travel, accommodation, and sustenance during treatment and follow-up visits constitute significant barriers. These economic constraints frequently result in missed appointments and treatment discontinuation, thereby compromising the effectiveness of established therapeutic protocols.

Addressing these barriers necessitates a multifaceted approach, including the strategic expansion of telemedicine services. Telehealth can serve as a vital tool to bridge gaps in cancer care accessibility, ensuring that patients receive timely and continuous treatment regardless of geographic location or socioeconomic status.

Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) is a leading institution in Pakistan, delivering comprehensive oncologic care to a large patient population. In 2024 alone, approximately 83,000 patients received radiotherapy in neoadjuvant, adjuvant, or palliative settings, underscoring the hospital's pivotal role in cancer management. As a high-volume cancer center, effective coordination of follow-up appointments and the maintenance of accurate clinical documentation are essential tasks that require seamless collaboration between patients and healthcare professionals.

Patients undergoing radiation therapy at SKMCH&RC were consecutively recruited and randomly assigned to either a hybrid follow-up group, receiving one virtual and one in-person appointment, or a control group receiving only in-person follow-ups. Clinical and demographic information was obtained from patient records. Following each visit, patients completed an anonymous, validated questionnaire survey assessing satisfaction, communication, and convenience. Additional logistical data, including appointment adherence, visit duration, and any technical difficulties during virtual visits, were systematically documented. All collected data were anonymized and stored securely to maintain confidentiality and support robust analysis of telehealth integration in on-treatment care.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are 18 years and above.
  • All patients who are undergoing radiotherapy (>5 fractions).
  • Capacity to provide informed consent for participation in the study.

Exclusion criteria

  • Patients below 18 years
  • Unable to provide informed consent for participation in the study.

Treatment and study plan

Primary outcomes

  1. Outcomes of virtual vs in person on treatment of follow-up radiotherapy visits through structured questionnaire

    Time frame: 4 weeks

    To evaluate the implementation of virtual and in person follow-up visits thereby accessing and comparing patient satisfaction with both modalities through structured questionnaire providing insights into clinical utility and overall acceptability of telehealth integration during active cancer treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Anusha Haider, MBBS

CONTACT

[email protected]

03244534247 ext. 4072

Sadia Anjum, MBBS

CONTACT

[email protected]

03280117652 ext. 4072

Sponsors and collaborators

Lead sponsor

Shaukat Khanum Memorial Cancer Hospital & Research Centre

Other

Registry information

Official study title

Transforming On-Treatment Follow-Up Care: A Randomized Controlled Trial of Virtual Versus In-Person Visits Evaluating Clinical Outcomes, Patient-Reported Measures, and Telehealth Implementation

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jul 24, 2026
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.